Clinical Trials

100 enrolled

Breast Neoplasms

NCT05411380 2022-11-04

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

73 enrolled

Breast Neoplasms

NCT04355858 2022-07-26

MULAN

319 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT04389073 2022-02-25

Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine

138 enrolled

Breast Neoplasms

NCT02595320 2021-12-20

X7-7

200 enrolled

BreastGastrointestinal

Breast Neoplasms, Gastrointestinal Neoplasms, Neoplasm Metastasis, Neoplasms

NCT04780347 2021-03-03

Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer

92 enrolled

Breast Neoplasms

NCT04681911 2020-12-23

Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer

71 enrolled

Breast Neoplasms

NCT04571437 2020-10-01

B-001

204 enrolled

Breast Neoplasms

NCT01917279 2020-07-23

CAMELLIA

280 enrolled

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Skin Diseases

NCT03044730 2020-07-13

Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery

30 enrolled 11 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04337658 2020-04-08

FAVOR

493 enrolled

Breast Neoplasms

NCT04307147 2020-03-13

NX in Luminal B Breast Cancer Patients After Neoadjuvant Chemotherapy

316 enrolled

Breast Neoplasms

NCT04302441 2020-03-10

A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy

550 enrolled

Breast Neoplasms

NCT04246502 2020-02-05

Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer

200 enrolled

Breast Neoplasms

NCT04095390 2019-09-19

INPHASE

60 enrolled

Breast Neoplasms

NCT03638648 2019-09-10

RSBNAT

80 enrolled

Breast Neoplasms

NCT04012918 2019-07-09

CONCEPT

124 enrolled

Breast Neoplasms

NCT03923166 2019-04-22

Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer

35 enrolled

Breast Neoplasms

NCT02592746 2019-04-08

A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC

182 enrolled

Breast Neoplasms

NCT03821454 2019-02-01

CALORIE

50 enrolled

Breast Neoplasms

NCT03647514 2018-12-10

Abraxane Combined With Xeloda as Neo-Adjuvant Chemotherapy in Early Breast Cancer

50 enrolled

Breast Neoplasms

NCT02028494 2018-09-07

CAP7/7

350 enrolled

Breast Neoplasms

NCT00301925 2018-08-08

TACT2

4,400 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT03465202 2018-03-14

Association of Capecitabine Pharmacokinetics and Toxicity With Aging

Phase 4 Unknown

100 enrolled

BreastGastrointestinal

Frailty, Breast Neoplasms, Colorectal Neoplasms

NCT03435666 2018-02-19

Capecitabine

Phase 1 Unknown

45 enrolled

BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms

NCT03423849 2018-02-06

The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy

Phase 2/3 Unknown

200 enrolled

Breast Neoplasms

NCT03359694 2017-12-02

Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer

300 enrolled

Breast Neoplasms, Genetic Predisposition to Disease

NCT00408408 2017-09-18

Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery

1,206 enrolled 19 charts

Breast Neoplasms

NCT02489409 2017-07-17

Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast Cancer

120 enrolled

Breast Neoplasms

NCT03204734 2017-07-02

Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer

132 enrolled

Breast Neoplasms

NCT01642771 2017-04-19

Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer

636 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00049244 2017-01-30

BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer

Phase 1 Unknown

Breast Neoplasms

NCT03006614 2017-01-16

PERS

320 enrolled

Breast Neoplasms

NCT02656589 2016-10-13

microRNA of Human Epidermal Growth Factor Receptor 2 （HER2）Positive Patient Treated With Herceptin

Unknown

300 enrolled

Breast Neoplasms

NCT02838238 2016-07-20

X Versus Placebo as Postoperative Adjuvant Treatment for Elder Breast Cancer

300 enrolled

Breast Neoplasms

NCT02597868 2016-03-29

A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep)

132 enrolled

Breast Neoplasms

NCT01939054 2015-06-04

Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients

90 enrolled

Breast Neoplasms

NCT01928680 2015-02-23

Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer

33 enrolled 5 charts